David Lauffer

Second-Generation Antibacterial Benzimidazole Ureas: Discovery of a Preclinical Candidate with Reduced Metabolic Liability

Anne‐Laure Grillot, Arnaud LeTiran, Dean Shannon et al. · Journal of Medicinal Chemistry · 2014 · 82 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3β

Michael Arnost, Al Pierce, Ernst ter Haar et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 66 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

A practical synthesis of (S) 3-tert-Butoxycarbonylamino-2-oxo-2,3,4,5-tetrahydro-1,5-benzodiazepine-1-acetic acid methyl ester as a conformationally restricted dipeptido-Mimetic for caspase-1 (ICE) inhibitors

David Lauffer, Michael D. Mullican · Bioorganic & Medicinal Chemistry Letters · 2002 · 45 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Design and Synthesis of m1-Selective Muscarinic Agonists:  (<i>R</i>)-(−)-(<i>Z</i>)-1-Azabicyclo[2.2.1]heptan-3-one, <i>O</i>-(3-(3‘-Methoxyphenyl)-2-propynyl)- oxime Maleate (CI<b>-</b>1017), a Functionally m1-Selective Muscarinic Agonist

Haile Tecle, Stephen D. Barrett, David Lauffer et al. · Journal of Medicinal Chemistry · 1998 · 29 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

The synthesis and evaluation of peptidyl aspartyl aldehydes as inhibitors of ice.

Michael D. Mullican, David Lauffer, Roger J. Gillespie et al. · Bioorganic & Medicinal Chemistry Letters · 1994 · 26 citations

Pharmacy, Chemistry, Medicinal Chemistry +8